Cellebrite Revolutionizes Investigative Workflow with Groundbreaking End-to-End Platform to Solve More Cases Faster

New Solution Suite Cements the Digital Forensic Giant’s Longstanding Leadership, delivering on the global promise of Justice Accelerated

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced Case-to-Closure (C2C), an expanded end-to-end platform for examiners and investigators to solve cases faster and more defensibly to accelerate justice around the world.

"Cellebrite C2C is our mission in action. This platform provides law enforcement with a new industry standard for excellence in examination and investigation and will equip professionals with a broader range of capabilities to clear backlogged cases like never before,” said Lisa Cole, Chief Marketing Officer at Cellebrite. "This platform will enable both public and private sector customers around the globe to accelerate their investigations, protect and save more lives across global communities. Building on our rich history for game-changing innovation, we are proud to be both the first, and the most tried and tested technology leaders in the Digital Investigation space.” 

As corporate professionals and law enforcement digital forensic units increasingly face overwhelming volumes of devices and data that threaten the speed and effectiveness of investigations, C2C offers multiple breakthrough technology solutions:

• Cellebrite Inseyets is an enhanced, automated digital forensics software technology designed to transform access, extraction and decoding of digital data across the broadest range of mobile phones and other digital sources. Cellebrite Inseyets equips our customers with the capabilities to surface more actionable insights faster from full file system extractions, including cloud data—minimizing the risk of leaving important evidence behind. Powered by market leading UFED and PA Ultra technology, Cellebrite Inseyets is designed to reduce examination time by up to 40% and allow agencies of all sizes to access up to 60% more data. It also enables examiners to expertly triage devices to determine relevancy to an investigation, saving precious time and maximizing scarce resources.
  
  Built with an enhanced workflow automation module, Forensic Labs and Investigative Units can accelerate data extraction and time-to-evidence, giving them a complete view of their investigation data, increasing efficiency, reducing human error and preserving evidence integrity for court.
  

• Enhancements to Cellebrite Pathfinder that connect data points from an unlimited amount of sources and gives investigators a big picture view of links between devices. With a new speech-to-text feature, investigators can easily locate specific words or phrases related to their cases that may have been otherwise buried or hidden within mountains of unstructured data. This enriched viewpoint is critical to create and complete the case story for investigators whose success relies on in-depth analysis.
  
  
• Additional Cellebrite Guardian features provide secure evidence storage, unit collaboration and the necessary chain of custody to ensure cases are protected from scrutiny. With Guardian, every player in the investigative process can securely and lawfully access needed data from anywhere, streamlining the evidentiary process.
  

You can learn more information about Cellebrite C2C here.

About Cellebrite 

Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, accelerate justice and preserve privacy in communities around the world. We are a global leader in Digital Investigative solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Investigative platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on Twitter at @Cellebrite. 

Caution Regarding Forward Looking Statements

This document includes "forward-looking statements” within the meaning of the "safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as "forecast,” "intend,” "seek,” "target,” "anticipate,” "will,” "appear,” "approximate,” "foresee,” "might,” "possible,” "potential,” "believe,” "could,” "predict,” "should,” "could,” "continue,” "expect,” "estimate,” "may,” "plan,” "outlook,” "future” and "project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include, but are not limited to, the following: estimated financial information for fiscal year 2023 and certain statements related to moving into the final quarter of the year with a compelling value proposition, attractive prospects to grow our wallet share with customers, and an increasingly efficient cost structure that supports ongoing profit improvement; our expectations for a strong, productive finish to 2023; revenue trending toward the upper half of our prior full-year 2023 expectations; and our belief that our continued progress in executing against our strategic priorities over the coming months will enable us to sustain our momentum into next year. Such forward-looking statements including those with respect to 2023 revenue, annual recurring revenue (ARR), adjusted EBITDA, operating profitability and earnings as well as commentary associated with future performance, strategies, prospects, and other aspects of Cellebrite’s business are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s DI solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; failure to manage its growth effectively; Cellebrite’s ability to introduce new solutions and add-ons; its dependency on its customers renewing their subscriptions; the low volume of business Cellebrite conducts via e-commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with higher costs or unavailability of materials used to create its hardware product components; fluctuations in foreign currency exchange rates; lengthy sales cycle for some of Cellebrite’s solutions; near term declines in new or renewed agreements; risks associated with inability to retain qualified personnel and senior management; the security of Cellebrite’s operations and the integrity of its software solutions; risks associated with the negative publicity related to Cellebrite’s business and use of its products; risks related to Cellebrite’s intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite’s operations in Israel, including the ongoing Israel-Hamas war and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled "Risk Factors” in Cellebrite’s annual report on Form 20-F filed with the SEC on April 27, 2023 and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission ("SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Media 

Victor Cooper 
Sr. Director of Corporate Communications + Content Operations 
Victor.cooper@cellebrite.com 
+1 404.804.5910 

Investor Relations 

Andrew Kramer 
Vice President, Investor Relations 
investors@cellebrite.com 
+1 973.206.7760